NCT07777419 Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease
| NCT ID | NCT07777419 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Parkinsons Disease (PD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-08-01 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With this study, the investigators want to investigate how deep brain stimulation (DBS) affects various cognitive and psychiatric symptoms of Parkinson's disease (PD). In particular, they will examine whether stimulation of the left hemisphere has a different effect than stimulation of the right hemisphere on cognitive and psychiatric symptoms.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Parkinson's disease * Treated with subthalamic nucleus deep brain stimulation (STN-DBS) * For part I: General research consent for the analysis of routine clinical data * For part II of the study: ability to provide informed consent * native German or French speaker * Montreal Cognitive Assessment with score ≥ 20 Exclusion Criteria: * Atypical Parkinsonism * Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.) * Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment * Schizophrenia, ongoing substance abuse, bipolar disorder or autism * For part II: Severe depressive disorder and/or suicidality * Insufficient quality or lack of brain imaging data pre and/or post STN-DBS
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07777419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Parkinsons Disease (PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07777419 currently recruiting?
Yes, NCT07777419 is actively recruiting participants. Contact the research team at deborah.amstutz@insel.ch for enrollment information.
Where is the NCT07777419 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT07777419 clinical trial?
NCT07777419 is sponsored by Insel Gruppe AG, University Hospital Bern. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.